Moreover, emerging evidence suggests that lncRNA expression may differ across MS subtypes—some lncRNAs, such as GAS5 and MEG3, appear more consistently dysregulated in RRMS, whereas data for SPMS or PPMS remain sparse. This evidence concerns the gene MEG3 and myeloid sarcoma.